{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:18:54Z","timestamp":1787854734916,"version":"build-2784847793"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["UM1 068617"],"award-info":[{"award-number":["UM1 068617"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["UM1 068617"],"award-info":[{"award-number":["UM1 068617"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["UM1 068617"],"award-info":[{"award-number":["UM1 068617"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["UM1 068617"],"award-info":[{"award-number":["UM1 068617"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["R01 AI179417"],"award-info":[{"award-number":["R01 AI179417"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["R01 AI179417"],"award-info":[{"award-number":["R01 AI179417"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["R01 AI179417"],"award-info":[{"award-number":["R01 AI179417"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>On-demand oral tenofovir disoproxil fumarate\u2013emtricitabine (TDF\/FTC) pre-exposure prophylaxis (PrEP) has been shown to be effective at preventing HIV acquisition among cisgender men and transgender women but is not recommended for cisgender women. On-demand PrEP may improve PrEP uptake, effective use, and persistence in cisgender women. We utilized published oral PrEP adherence-efficacy curves and data from HPTN 067 study to estimate effectiveness of different non-daily PrEP options when used by cisgender women and investigate which sub-groups may benefit most from on-demand PrEP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We created a synthetic cohort of PrEP users with data on sex act frequency and pill taking from the HPTN 067 Cape Town site. We simulated PrEP use with three PrEP regimens tested in HPTN 067: daily, time-driven (2 pills\/week+1 pill after sex), and event-driven (1 pill before+1 pill after sex) PrEP, and hypothesized 2-1-1 PrEP (2 pills before+1 pill each of the two days after sex) for six months each. We estimated PrEP effectiveness based on the number of pills taken around sex acts. Adherence to 2-1-1 PrEP, which was not tested in the HPTN 067, was informed by observed adherence to event-driven PrEP. Assignment to 2-1-1 PrEP based on daily PrEP adherence and sex act frequency was also analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We estimated median effectiveness of 86% for daily, 47% for time-driven, 42% for event-driven, and 57% for 2-1-1 PrEP. PrEP users with low adherence to daily PrEP (less than 2.8 pills per week) benefited most from on-demand PrEP. In this subgroup, comprising 8% of the cohort, PrEP effectiveness increased from 41% to 44% when switching from daily to 2-1-1 PrEP while pill taking decreased from 2.2 to 1.4 pills per week; population-level effectiveness was unchanged when this subgroup switched to on-demand PrEP. We found no advantage in assigning 2-1-1 PrEP by sex act frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our model suggests that on-demand PrEP could benefit women with low daily PrEP adherence by decreasing the number of days when pills need to be taken and modestly increasing effectiveness compared to a daily regimen. This would be a valuable and easy-to-implement additional option in places where daily oral PrEP is already available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0357094","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:28:32Z","timestamp":1787851712000},"page":"e0357094","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimated benefits of providing on-demand pre-exposure prophylaxis options for cisgender women in South Africa: A modeling study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3251-8501","authenticated-orcid":true,"given":"Sarah E.","family":"Stansfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3919-006X","authenticated-orcid":true,"given":"Marie-Claude","family":"Boily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-7480","authenticated-orcid":true,"given":"Deborah","family":"Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobromir T.","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"5","key":"pone.0357094.ref001","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0357094.ref002","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women","volume":"375","author":"JM Baeten","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0357094.ref003","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women","volume":"375","author":"A Nel","year":"2016","journal-title":"N Engl J Med"},{"issue":"10337","key":"pone.0357094.ref004","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"S Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"issue":"13","key":"pone.0357094.ref005","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women","volume":"391","author":"L-G Bekker","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"pone.0357094.ref006","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"J-M Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0357094.ref007","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel","volume":"333","author":"RT Gandhi","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"pone.0357094.ref008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1742-6405-10-30","article-title":"Women and HIV in Sub-Saharan Africa","volume":"10","author":"G Ramjee","year":"2013","journal-title":"AIDS Res Ther"},{"key":"pone.0357094.ref009","doi-asserted-by":"crossref","first-page":"20227","DOI":"10.7448\/IAS.18.4.20227","article-title":"Rethinking HIV prevention to prepare for oral PrEP implementation for young African women","volume":"18","author":"CL Celum","year":"2015","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0357094.ref010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/09540121.2022.2032573","article-title":"Four years later: Do South Africans know what pre-exposure prophylaxis for HIV is?","volume":"35","author":"F Haffejee","year":"2023","journal-title":"AIDS Care"},{"key":"pone.0357094.ref011","doi-asserted-by":"crossref","first-page":"691729","DOI":"10.3389\/fpubh.2022.691729","article-title":"\u201cWhatever is in the ARVs, is Also in the PrEP\u201d Challenges Associated With Oral Pre-exposure Prophylaxis Use Among Female Sex Workers in South Africa","volume":"10","author":"NF Makhakhe","year":"2022","journal-title":"Front Public Health"},{"issue":"12","key":"pone.0357094.ref012","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1007\/s10461-022-03721-6","article-title":"Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial","volume":"26","author":"RJ Munthali","year":"2022","journal-title":"AIDS Behav"},{"issue":"5","key":"pone.0357094.ref013","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26496","article-title":"Dosing forgiveness of oral PrEP for cisgender women remains uncertain","volume":"28","author":"M Moore","year":"2025","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pone.0357094.ref014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine","volume":"214","author":"ML Cottrell","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0357094.ref015","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1038\/s41467-026-72907-6","article-title":"Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men","volume":"17","author":"S Iannuzzi","year":"2026","journal-title":"Nat Commun"},{"issue":"151","key":"pone.0357094.ref016","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"PL Anderson","year":"2012","journal-title":"Sci Transl Med"},{"issue":"3","key":"pone.0357094.ref017","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention","volume":"66","author":"D Donnell","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"pone.0357094.ref018","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/cid\/ciad021","article-title":"Updating the Adherence-Response for Oral Emtricitabine\/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women","volume":"76","author":"PL Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pone.0357094.ref019","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1038\/s41591-023-02564-5","article-title":"Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence","volume":"29","author":"M Moore","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"pone.0357094.ref020","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.2024.0464","article-title":"HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women","volume":"331","author":"J Marrazzo","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"pone.0357094.ref021","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41591-023-02615-x","article-title":"Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women","volume":"29","author":"L Zhang","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"pone.0357094.ref022","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jama.2024.0432","article-title":"Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women","volume":"331","author":"AN Sheth","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"pone.0357094.ref023","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10461-024-04529-2","article-title":"HIV Prevention Product Acceptability and Preference Among Women in Sub-Saharan Africa to Inform Novel Biomedical Options in Development: A Systematic Review","volume":"29","author":"W Makoni","year":"2025","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0357094.ref024","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2989\/16085906.2022.2039727","article-title":"\u201cI prefer to take pills when I plan to have sex\u201d: Perceptions of on-demand versus daily oral pre-exposure prophylaxis among adolescents in Kampala, Uganda","volume":"21","author":"R Kawuma","year":"2022","journal-title":"Afr J AIDS Res"},{"issue":"6","key":"pone.0357094.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287627","article-title":"A qualitative study to explore daily versus on-demand oral pre-exposure prophylaxis (PrEP) in young people from South Africa, Uganda and Zimbabwe","volume":"18","author":"JJ Dietrich","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"pone.0357094.ref026","article-title":"Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067\/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial","volume":"5","author":"L-G Bekker","year":"2018","journal-title":"Lancet HIV"},{"issue":"11","key":"pone.0357094.ref027","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/cid\/cix1086","article-title":"Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067\/ADAPT Study","volume":"66","author":"RM Grant","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0357094.ref028","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40121-017-0159-9","article-title":"A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective","volume":"6","author":"JL Bailey","year":"2017","journal-title":"Infect Dis Ther"},{"key":"pone.0357094.ref029","doi-asserted-by":"crossref","first-page":"101776","DOI":"10.1016\/j.eclinm.2022.101776","article-title":"Estimating benefits of using on-demand oral prep by MSM: A comparative modeling study of the US and Thailand","volume":"56","author":"SE Stansfield","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"12","key":"pone.0357094.ref030","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00227-8","article-title":"Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial","volume":"10","author":"G Nair","year":"2023","journal-title":"Lancet HIV"},{"issue":"5","key":"pone.0357094.ref031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251917","article-title":"Facilitators and barriers of 2-1-1 HIV pre-exposure prophylaxis","volume":"16","author":"C Camp","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"pone.0357094.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"J Zhang","year":"2022","journal-title":"Lancet HIV"},{"issue":"8","key":"pone.0357094.ref033","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26154","article-title":"A decision support tool has similar high PrEP uptake and increases early PrEP persistence in adolescent girls and young women in South Africa: results from a randomized controlled trial","volume":"26","author":"C Celum","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"pone.0357094.ref034","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkaa476","article-title":"Two-dose emtricitabine\/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection","volume":"76","author":"E Bekerman","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"pone.0357094.ref035","article-title":"Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection","volume":"2","author":"JG Garc\u00eda-Lerma","year":"2010","journal-title":"Sci Transl Med"},{"issue":"11","key":"pone.0357094.ref036","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1007\/s10461-021-03360-3","article-title":"Qualitative Assessment of Barriers and Facilitators of PrEP Use Before and After Rollout of a PrEP Program for Priority Populations in South-central Uganda","volume":"25","author":"W Ddaaki","year":"2021","journal-title":"AIDS Behav"},{"issue":"4","key":"pone.0357094.ref037","article-title":"Impact of pill sharing on drug resistance due to a wide-scale oral prep intervention in generalized epidemics","author":"D Dimitrov","year":"2012","journal-title":"J AIDS Clin Res"},{"key":"pone.0357094.ref038","article-title":"Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis","author":"SE Stansfield","year":"2023","journal-title":"J Int AIDS Soc"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:28:40Z","timestamp":1787851720000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357094"}},"subtitle":[],"editor":[{"given":"Max","family":"von Kleist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357094","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}